WALTHAM, Mass., Sept. 8 /PRNewswire-FirstCall/ -- Thermo Electron Corporation today announced the introduction of three new mass spectrometers: the Finnigan(TM) LXQ(TM) Linear Ion Trap Mass Spectrometer for high-throughput drug discovery and proteomics; the DELTA V Series Isotope Ratio Mass Spectrometer for earth sciences research; and the DFS High Resolution Magnetic Sector Mass Spectrometer for high-precision environmental analysis. These new product introductions continue a year marked by a number of significant advancements in Thermo's mass spectrometry portfolio, including the introduction of the LTQ(TM) Orbitrap(TM) hybrid mass spectrometer, the first totally new mass analyzer to be introduced to the market in over 20 years, and the acquisition of Ionalytics to obtain a key patented ion separation technology.
"Thermo has successfully executed its strategy to build the most comprehensive mass spectrometry product offering of any company in the industry," said Marc Casper, senior vice president of Thermo Electron. "Through our aggressive R&D efforts and our focused acquisition strategy, we are uniquely able to satisfy the needs of both our life sciences and industrial customer bases. I am more excited than ever about our market position and our opportunity for growth."
Today's New Product Launches
The Finnigan LXQ Linear Ion Trap Mass Spectrometer advances high- throughput drug discovery and proteomics by making linear trap performance a cost-effective option for fast-paced analytical laboratories. The Finnigan LXQ offers novel patented ion trap technology that delivers ultra fast cycle times and improved ion statistics, resulting in dramatically superior sensitivity and speed over 3D ion traps.
The DELTA V Series of gas isotope ratio mass spectrometers includes the DELTA V Advantage and the DELTA V Plus. The technology offers excellent linearity and stability in a new compact design that requires less laboratory space.
The DFS, a new high-resolution double-focusing magnetic sector GC-MS, is the most sensitive, reliable and comprehensive instrument for target compound analysis available on the market. This technology will be used primarily to perform trace compound analyses of environmental samples such as dioxins, as well as for sports doping.
Other Recent Mass Spectrometry Announcements
In August, Thermo announced the acquisition of Ionalytics. Ionalytics provides Thermo with a dynamic ion filtering device, developed using patented High-Field Asymmetric Waveform Ion Mobility Spectrometry (FAIMS) technology. FAIMS technology enables a novel method to separate ions that cannot be done easily or consistently using any other technique or combination of techniques.
Thermo's breakthrough hybrid mass spectrometer, the LTQ Orbitrap, was launched at the ASMS Conference on Mass Spectrometry in June. The LTQ Orbitrap combines patented Orbitrap technology with the highly successful Finnigan LTQ linear ion trap, enabling faster, more sensitive and more reliable detection and identification of compounds in complex mixtures. Its outstanding mass accuracy, mass resolution and reliable high sensitivity MSn performance make it a strong alternative to existing hybrid Time-of-Flight systems. The LTQ Orbitrap offers optimum performance for small molecule research, drug discovery, proteomics, metabolite identification and metabolomics.
For key quantitative pharmaceutical bioanalysis applications, Thermo also recently announced that the sensitivity and utility of Thermo's high resolution Finnigan TSQ Quantum(TM) Ultra has been significantly enhanced with a new heated ionization probe (H-ESI) along with the seamless Watson LIMS- Xcalibur digital interface designed to promote compliance with GLP standards, and 21 CFR Part 11 regulations.
In addition to these latest advances, Thermo continues to be a leader in a number of other MS instrument types, including quadrupole and ion trap GC-MS, and quadrupole and high resolution magnetic sector ICP-MS for elemental analysis. These systems are used extensively in a multitude of applications, especially environmental analysis.
About Thermo Electron Corporation
Thermo Electron Corporation is the world leader in analytical instruments. Our instrument solutions enable our customers to make the world a healthier, cleaner and safer place. Thermo's Life and Laboratory Sciences segment provides analytical instruments, scientific equipment, services and software solutions for life science, drug discovery, clinical, environmental and industrial laboratories. Thermo's Measurement and Control segment is dedicated to providing analytical instruments used in a variety of manufacturing processes and in-the-field applications, including those associated with safety and homeland security. Based near Boston, Massachusetts, Thermo has revenues of more than $2.7 billion, and employs approximately 11,000 people in 30 countries. For more information, visit http://www.thermo.com/.
The following constitutes a "Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: This press release contains forward- looking statements that involve a number of risks and uncertainties. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are set forth under the heading "Forward-Looking Statements" in the company's Quarterly Report on Form 10-Q for the fiscal quarter ended July 2, 2005. These include risks and uncertainties relating to: the need to develop new products and adapt to significant technological change; dependence on customers that operate in cyclical industries; general worldwide economic conditions and related uncertainties; the effect of changes in governmental regulations; dependence on customers' capital spending policies and government funding policies; use and protection of intellectual property; exposure to product liability claims in excess of insurance coverage; retention of contingent liabilities from businesses we sold; realization of potential future savings from new productivity initiatives; implementation of our branding strategy; implementation of strategies for improving internal growth; the effect of exchange rate fluctuations on international operations; identification, completion and integration of new acquisitions and potential impairment of goodwill from previous acquisitions. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.
Media Contact Information: Investor Contact Information:
Lori Gorski Kenneth J. Apicerno
Phone: 781-622-1242 Phone: 781-622-1111
E-mail:
